Wrapmanager Inc. Trims Position in Eli Lilly and Company $LLY

Wrapmanager Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 22.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,337 shares of the company’s stock after selling 666 shares during the period. Wrapmanager Inc.’s holdings in Eli Lilly and Company were worth $1,783,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Palumbo Wealth Management LLC lifted its position in Eli Lilly and Company by 4.2% during the 3rd quarter. Palumbo Wealth Management LLC now owns 1,035 shares of the company’s stock worth $790,000 after acquiring an additional 42 shares during the period. Apriem Advisors raised its stake in shares of Eli Lilly and Company by 12.9% during the third quarter. Apriem Advisors now owns 1,940 shares of the company’s stock worth $1,480,000 after purchasing an additional 221 shares during the last quarter. Mufg Securities Americas Inc. lifted its holdings in shares of Eli Lilly and Company by 23.0% during the third quarter. Mufg Securities Americas Inc. now owns 21,439 shares of the company’s stock worth $16,358,000 after purchasing an additional 4,005 shares during the period. Lake Street Private Wealth LLC grew its position in Eli Lilly and Company by 4.0% in the 3rd quarter. Lake Street Private Wealth LLC now owns 6,559 shares of the company’s stock valued at $5,004,000 after buying an additional 250 shares during the last quarter. Finally, Baldwin Investment Management LLC grew its position in Eli Lilly and Company by 15.7% in the 3rd quarter. Baldwin Investment Management LLC now owns 11,079 shares of the company’s stock valued at $8,453,000 after buying an additional 1,505 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A late‑stage head‑to‑head trial showed Novo Nordisk’s next‑generation obesity drug (CagriSema) failed to achieve non‑inferiority vs. Lilly’s tirzepatide, spurring a sharp selloff in Novo and lifting confidence that Lilly will retain share leadership in the fast‑growing obesity market. Novo’s stumbles burnish Lilly’s widening lead in weight-loss drugs
• Positive Sentiment: The FDA approved and Lilly launched a four‑dose, single‑patient KwikPen for Zepbound (tirzepatide), offering a one‑month‑per‑pen option at the same self‑pay price — a product change that should help adherence/retention and reduce friction for payers and patients. Zepbound now available in multi-dose KwikPen
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and a $1,260 price target, calling Lilly’s 2026 guide conservative while highlighting a diversified pipeline and capital flexibility — an analyst endorsement that supports the stock’s valuation and investor sentiment. Goldman Sachs maintains Buy on Eli Lilly
• Positive Sentiment: Additional pipeline wins: Lilly reported positive combo data (Taltz + Zepbound) in overweight/obese psoriasis patients and expanded licensing activity, underscoring growth avenues beyond obesity/diabetes. These items support longer‑term EPS upside. Pipeline expansion and positive trial data
• Neutral Sentiment: Institutional flows and price targets remain constructive (median analyst targets around $1,250+), which underpins sentiment, but these are already priced into today’s move. Analyst and flow commentary
• Neutral Sentiment: Some commentary notes LLY has recently trailed the S&P 500 on a short‑term basis — a reminder that momentum and macro factors can temper performance even with strong fundamentals. Is Eli Lilly Stock Underperforming the S&P 500?
• Negative Sentiment: High levels of insider/large‑holder sales (noted in recent reports) could be viewed as a cautionary signal for some investors, though context (estate/institutional rebalancing) matters. Watch insider activity for confirmation. QuiverQuant: insider & institutional activity

Analyst Ratings Changes

Several analysts have recently commented on the stock. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 2nd. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Truist Financial set a $1,281.00 target price on Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,228.54.

Eli Lilly and Company Trading Up 4.7%

Shares of LLY stock opened at $1,057.38 on Tuesday. The stock has a market cap of $997.49 billion, a P/E ratio of 46.07, a P/E/G ratio of 1.17 and a beta of 0.39. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The business has a fifty day simple moving average of $1,054.73 and a 200-day simple moving average of $920.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the company earned $5.32 EPS. The firm’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 30.15%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.